Vaccines

Fresh off its 'Fierce 15' win, Recludix Pharma and its billion-dollar Sanofi pact take the spotlight with a novel oral drug for inflammatory diseases.

With a device that calms deadly 'cytokine storms,' SeaStar Medical targets vast new markets, but can the small company deliver on its huge promises?

With its lead asset TEC-001 targeting tough liver cancers, Teclison's presence at the ASCO GI Symposium puts its innovative approach in the spotlight.

With enrollment complete for three major trials, MediciNova braces for a transformative year with crucial data expected for its ALS and metabolic disease candidates.

With its first drug for a rare disease now on the market, Stealth BioTherapeutics bets its future on a deep pipeline targeting mitochondrial dysfunction.

With a key presentation looming, Star Therapeutics aims to showcase its universal hemostatic therapy, VGA039, for von Willebrand disease.

With pivotal Phase 2 data for its non-invasive skin cancer patch due in Q1, Medicus Pharma is advancing a diverse pipeline fueled by AI and strategic acquisitions.

South Korea's Curogen secures major national funding and targets global partners at the JP Morgan conference, advancing novel therapies for IBD and HS.

Formerly Cybin, Helus Pharma's Nasdaq launch marks a pivotal shift towards commercializing its breakthrough depression and anxiety drug pipeline.

A new drug could redefine life for polycythemia vera patients, replacing frequent, burdensome blood draws with a simple weekly self-injection.

Abingworth elevates Bali Muralidhar and hires Travis Wilson, signaling a major push into clinical co-development and buyouts under Carlyle's wing.

Amid a crucial patent appeal and a competitive market, Scilex Holding hires renowned trial lawyer Marc Kasowitz, signaling an aggressive new legal strategy.

Lantheus sells its legacy SPECT business to fusion-tech firm SHINE, sharpening its focus on high-growth PET diagnostics and next-gen cancer therapies.

With patent cliffs looming and big bets on M&A, all eyes are on BMS to prove its growth strategy and high-stakes pipeline can deliver in 2026.

Dr. Lu Xianping, crowned EY Entrepreneur Of The Year, didn't just invent new drugs; he helped reinvent China's entire pharmaceutical industry.

The biopharma investment giant has now acquired 100% of the royalty stream for Roche's blockbuster SMA drug, a strategic move years in the making.

The Danish firm scraps its 2025 revenue forecast, accepting a larger loss in a bold move to secure more lucrative future deals for its key drug candidates.

INOVIO's promising non-surgical treatment for a rare disease faces FDA scrutiny, casting doubt on its fast-track approval and impacting patient hopes.

A pivotal trial for an acute myeloid leukemia drug is delayed for a promising reason: patients are surviving longer than anticipated, fueling cautious optimism.

A new partnership with logistics giant Uniphar will bring Zevra's breakthrough NPC therapy, MIPLYFFA, to patients in underserved regions worldwide.